VOR: Vor Biopharma Inc

VOR新闻

• 12:38 William Blair Initiates Coverage On Vor Biopharma with Outperform Rating
• 12:38 威廉·布莱尔开始覆盖 Vor Biopharma，评级为“跑赢大盘”
• 12:07 Vor Bio Announces Data Phase 3 Trial Of Telitacicept By Its RemeGen Partner Demonstrates Over 95% Participants Achieved At Least 5-Point MG-ADL Improvement Over 48 Weeks
• 12:07 Vor Bio宣布：其合作伙伴荣昌生物开展的泰它西普3期数据试验显示，超过95%的参与者在48周内实现了至少5分的MG-ADL改善
• 08:48 Vor Biopharma: A Funded Replication Story With Franchise Potential (NASDAQ:VOR)
• 23:57 Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
• 13:55 Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
• 13:55 Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?
• 19:38 Vor Biopharma: It's A Game Of Wait And See (NASDAQ:VOR)
• 16:00 Vor Biopharma (VOR) Upgraded to Buy: Here's Why
• 13:55 Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know